Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9852W HIGH $43.74
Volume
2.90 K
Value Traded
167.44 K
Short % Float
1.96%
-3.87%Week
-7.45%1 Month
+0.21%3 Month
+31.48%6 Month
-99.98%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.67 M
EPS (TTM)
-231.49
P/E Ratio
-
Ent. Value
-889.25 K
Total Shares
565.69 K
Float Shares
560.00 K
Insiders
1.85%
Institutions
9.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SPRC Catalyst Timeline
Dated clinical, regulatory and corporate events for SciSparc Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SciSparc Ltd.
335Total events
2Upcoming
86Tier-1 (high impact)
2017 to 2026Coverage
Upcoming catalysts 2
TBD
T1Acquisition
Subscribe to view catalyst details
TBD
T2Orphan Drug Designation
Subscribe to view catalyst details
Event history 50
●Composition Patent FiledIP / Competition
Three U.S. patent applications published covering LSD, ketamine and ibogaine combinations with PEA
depression, PTSD, pain, substance use disorderssource ↗
▲Partnership / LicenseCorporate
NeuroThera engages RK Strategies for government and public affairs consulting
▲Trial InitiationSCI-110Trial
Initiation of Phase IIb program for SCI-110 in Tourette Syndrome
Tourette Syndromesource ↗
▲Enrollment UpdateSCI-210Trial
Enrollment reaches 26 of planned 60 children in SCI-210 autism trial
autism spectrum disordersource ↗
▲Patent GrantedIP / Competition
U.S. patent application publication covering MDMA-N-acylethanolamines combination
▲Patent GrantedIP / Competition
Japanese patent granted for NeuroThera's pharmacological combination
▲Trial InitiationSCI-110Trial
Initiation of Phase IIb clinical trial site at Yale Child Study Center
Tourette Syndromesource ↗
▲Platform ValidationPreclinical
NeuroThera completes internal validation of quantum sampling workflow
▲Trial InitiationSCI-110Trial
Initiation of Phase IIb clinical trial at Hannover Medical School for SCI-110 in Tourette Syndrome
Tourette Syndromesource ↗
▲IND ClearanceSCI-110IND
Regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and ethics committee approval
Tourette Syndromesource ↗
◆Other Regulator MilestoneEx-US Regulatory
Outside date for completion of Transaction extended to June 1, 2026
▲Other Regulator MilestoneEx-US Regulatory
NeuroThera received conditional regulatory approval from TSX for acquisition of 54% interest in CliniQuantum
●Partnership / LicenseCorporate
Amendment to SPA to address TSX comment on minimum price and lock-up arrangements
●Composition Patent FiledIP / Competition
Patent application filed for MEAI-PEA combination therapy for MDD
major depressive disordersource ↗
▲Patent GrantedIP / Competition
Publication of international patent application for MEAI-PEA combination therapy
weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD)source ↗
◆AcquisitionCorporate
NeuroThera signs definitive agreement to acquire 54.01% stake in CliniQuantum
▲Product LaunchMUSEPost-Market
SciSparc intends to commence commercialization of MUSE system immediately after transaction closing
gastroesophageal reflux disease (GERD)source ↗
▲Partnership / LicenseCorporate
NeuroThera entered into share purchase agreement to acquire 54% of CliniQuantum
▲Patent GrantedIP / Competition
U.S. patent granted for cannabinoid-enhanced antimicrobial platform
antimicrobial resistance (MRSA)source ↗
◆AcquisitionCorporate
SciSparc acquires IP portfolio including MUSE system from Xylo Technologies
▲Product LaunchMUSEPost-Market
Immediate commercialization of MUSE system following acquisition
GERDsource ↗
◆AcquisitionCorporate
SciSparc signs definitive agreement to acquire patent portfolio for MUSE system from Xylo Technologies
▼Quarterly UpdateCorporate
Received Nasdaq notification of minimum stockholders' equity non-compliance
▲Patent GrantedIP / Competition
Israel Patent Office granted patent for opioid and N-acylethanolamine combination
pain reliefsource ↗
▲Partnership / LicenseCorporate
SciSparc signs binding term sheet to acquire MUSE system IP from Xylo
GERDsource ↗
▲Partnership / LicenseCorporate
SciSparc signs binding term sheet to acquire MUSE system IP from Xylo
gastroesophageal reflux diseasesource ↗
●Composition Patent FiledIP / Competition
Israeli patent application filed for combination therapy of MEAI and PEA for depression
depressionsource ↗
●Quarterly UpdateCorporate
Interim consolidated financial statements for six months ended June 30, 2025
◆AcquisitionCorporate
SciSparc acquires controlling interest in Neurothera Labs Inc. (formerly Miza III Ventures Inc.)
◆Other Regulator MilestoneEx-US Regulatory
Neurothera shares expected to resume trading on TSXV under symbol NTLX
◆Timing GuidancePresentation
Anticipated closing of Proposed Transaction on or around October 22, 2025
▲Patent GrantedIP / Competition
U.S. patent application published for MEAI and PEA combination therapy targeting binge behavior disorders
binge behavior disorderssource ↗
◆AcquisitionCorporate
SciSparc enters into definitive agreement to acquire controlling interest in Miza III Ventures Inc.
◆AcquisitionCorporate
Framework agreement for mutual termination of merger with AutoMax Motors
●Platform ValidationPreclinical
Board resolves to launch quantum computing-enabled 3D protein modeling initiative
●Platform ValidationPreclinical
Board resolved to initiate quantum computing 3D protein modeling initiative
◆Quarterly UpdateCorporate
Special meetings of AutoMax shareholders to vote on merger approval
◆Quarterly UpdateCorporate
Special meeting of SciSparc shareholders to vote on merger approval
▲Composition Patent FiledIP / Competition
International patent application published for combination therapy of MEAI and PEA for metabolic syndrome and obesity
metabolic syndrome and obesitysource ↗
Past FDA Catalysts and PDUFA Decisions
How SPRC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$1M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.5x
rNPV / MCap
Top 81%
Micro Cap(rank 533 of 658)
Percentile Rank
SciSparc Ltd. faces pipeline headwinds (26/100), with $115M risk-adjusted pipeline value, led by SCI-110 in Tourette Syndrome (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SCI-110 Small moleculeNCT05126888 | Tourette Syndrome | Phase 2 | NOT YET_RECRUITING | 164 | Feb 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every SPRC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SCI-110 | Tourette Syndrome | Phase 2b | 2026-08-05 | average tic reduction of 21% across the entire participants sampleRead More | SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette SyndromeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shrem ItschakDirector | Sell | -462 10,596 held | $10.00 | 06/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SPRC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SPRC for Q2 2026. | ||||
SPRC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SPRC ranks across every disease it competes in
Competitive Position is a premium feature
See how SPRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSPRC News
SPRC▲ +9.6%on this news
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
SciSparc Ltd. announced that its subsidiary NeuroThera has expanded its U.S. patent portfolio through collaboration with Clearmind Medicine. The new patent applications cover combinations of PEA technology with LSD, ketamine, and ibogaine, targeting mental health disorders such as depression and PTSD. This collaboration aims to develop safer and more effective treatments for various neuropsychiatric conditions.
Read more →SPRCSciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc's subsidiary, NeuroThera Labs, is seeking FDA Orphan Drug Designation for SCI-110, a treatment for adult Tourette Syndrome. The engagement of RK Strategies aims to boost visibility and support regulatory pathways. SCI-110 has shown promising early clinical results, achieving a 21% tic reduction in Phase IIa trials, and is now advancing into Phase IIb trials across multiple academic centers.
Read more →SPRC▼ -14.5%on this newsshared move
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has made significant progress in enrolling participants for the SCI-210 clinical trial aimed at treating autism spectrum disorder. With 26 out of 60 children enrolled, the trial evaluates the safety and efficacy of SCI-210, a combination of CBD and CannAmide™, over a 20-week period. The study is designed to assess whether this dual-compound treatment is more effective than CBD alone.
Read more →SPRCSciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
SciSparc Ltd. has appointed Prof. Carmel Domshlak, a prominent AI researcher, to its Scientific Advisory Board, effective September 1, 2026. This move aims to bolster the company's capabilities in the Agentic AI market. Prof. Domshlak's extensive experience and accolades in AI research will support SciSparc's strategic focus on this rapidly evolving field.
Read more →SPRCSciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
SciSparc Ltd. announced the publication of a patent application for a combination of MDMA and N-acylethanolamines aimed at treating PTSD, anxiety, and eating disorders. This development is part of a collaboration with Clearmind Medicine, which has resulted in a significant intellectual property portfolio. The FDA's recent guidance on psychedelic drugs further supports the regulatory framework for this collaboration.
Read more →SPRCSciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
SciSparc Ltd. has announced that its subsidiary, NeuroThera Labs, completed a C$5.4 million financing round, with SciSparc contributing C$2.7 million. Following this investment, SciSparc holds approximately 44.6% of NeuroThera's shares, valued at C$30 million. The funds will be used for general working capital and corporate expenses.
Read more →SPRCSciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
SciSparc Ltd.'s subsidiary, NeuroThera Labs, has been granted a Japanese patent for its innovative pharmacological combination aimed at enhancing the efficacy of 4-aminophenol derivatives. This patent is a significant milestone for NeuroThera as it expands its intellectual property and aims to modernize treatments for pain and fever. The combination therapy is designed to potentially lower dosing and mitigate side effects.
Read more →SPRCSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
SciSparc Ltd. announced the launch of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Yale Child Study Center. The trial aims to evaluate the efficacy and safety of SCI-110, building on positive results from a previous Phase IIa study. The study is also being conducted at sites in Germany and Israel, addressing a significant unmet medical need.
Read more →SPRC▼ -18.2%on this newsshared move
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
SciSparc Ltd. announced a significant achievement by its subsidiary, NeuroThera Labs, in developing a hybrid quantum-classical workflow for clinical data analytics. This platform can process real-world clinical data and generate interpretable insights, enhancing the analysis of complex biomedical datasets. Future plans include optimizing algorithms and expanding dataset capabilities.
Read more →SPRC▲ +70.5%on this newsshared move
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has validated a quantum sampling workflow for clinical data analysis. This platform, developed in collaboration with an S&P 500 company, aims to enhance the analysis of large-scale clinical datasets. The validation marks a significant step toward advanced quantum-enabled analytical capabilities in healthcare.
Read more →SPRC▼ -6%on this news· ran to +63% by day 3shared move
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
SciSparc Ltd. has announced its decision to enter the agentic AI market and establish a Scientific Advisory Board focused on AI and cybersecurity. The company is currently evaluating opportunities and engaging in discussions with several firms in the AI sector. This move reflects SciSparc's strategic growth initiatives while continuing its focus on cannabinoid pharmaceuticals.
Read more →SPRC▲ +14.8%on this news· ran to +26% by day 1
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
SciSparc Ltd. has announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School in Germany. This trial follows positive results from a Phase IIa study, which indicated a significant reduction in tic severity. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65.
Read more →SPRC▲ +22%on this news
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has completed the acquisition of a 54% interest in CliniQuantum. This acquisition, valued at approximately CAD$9.46 million, aims to leverage CliniQuantum's technology for improving clinical trial outcomes. The deal includes potential earn-out payments based on future milestones, highlighting the strategic focus on central nervous system disorders.
Read more →SPRC▲ +140.3%on this news
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, received conditional regulatory approval from the TSX for acquiring a 54% interest in CliniQuantum. The acquisition involves issuing approximately 56.6 million common shares of NeuroThera to CliniQuantum's shareholders. This strategic move aims to enhance NeuroThera's capabilities in developing novel treatments for central nervous system disorders.
Read more →SPRCSciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
SciSparc Ltd. has announced a collaboration with NeuroThera Labs and Clearmind Medicine, resulting in a patent application for a new therapy targeting major depressive disorder. This innovative treatment combines MEAI and PEA, potentially offering a non-hallucinogenic alternative to traditional antidepressants. The patent filing highlights the promise of this combination in addressing depression, a major global health concern.
Read more →SPRC▲ +22.9%on this newsshared move
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc Ltd. announced a collaboration with NeuroThera Labs and Clearmind Medicine to publish an international patent for a novel therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). The combination therapy of MEAI and PEA aims to provide a safer alternative to existing treatments. This development comes amid a rapidly growing market for weight loss drugs, projected to reach $226 billion by 2035.
Read more →SPRC▼ -28.3%on this newsshared move
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has signed a definitive agreement to acquire a 54.01% stake in CliniQuantum. This acquisition aims to leverage CliniQuantum's quantum technology to enhance clinical trial processes. The transaction is valued at approximately $9.46 million, with additional earn-out payments based on specific milestones. The closing is expected to occur within 30 days after applying for an Israeli tax ruling, anticipated around March 31, 2026.
Read more →SPRC▼ -9.9%on this news
SciSparc Announces 1-for-9 Reverse Share Split
SciSparc Ltd. announced a one-for-nine reverse share split effective March 4, 2026. Following the split, the company will have approximately 565,000 outstanding shares, with no changes to shareholders' ownership percentages. The split aims to improve the company's stock price and market perception while maintaining its Nasdaq trading symbol.
Read more →SPRC▼ -9.9%on this newsshared move
SciSparc Announces 1-for-9 Reverse Share Split Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel
SciSparc Ltd. announced a 1-for-9 reverse share split effective on March 4, 2026. After the split, the company will hold approximately 565,000 outstanding shares, with about 561,533 publicly held. The decision was approved by shareholders at the Annual General Meeting held on June 26, 2025, and is intended to adjust the share structure without altering ownership percentages significantly. No fractional shares will be issued as a result of the split, and trading will continue under the existing symbol 'SPRC'.
Read more →SPRCSciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
SciSparc Ltd. announced that NeuroThera Labs has been granted a U.S. patent for a novel cannabinoid-enhanced platform aimed at overcoming antibiotic resistance, specifically targeting MRSA. This technology combines traditional antibiotics with cannabinoids to enhance their effectiveness against resistant bacterial strains. The patent strengthens NeuroThera's intellectual property and addresses the urgent need for innovative solutions in the face of rising antimicrobial resistance.
Read more →About SciSparc Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next SPRC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime